- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實驗
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細胞核與細胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 新產(chǎn)品
- 聯(lián)系我們
Napabucasin (BBI608)
別名: BBI608
Napabucasin (BBI608) 是一種口服具有活性的Stat3和癌細胞多能性抑制劑。
Napabucasin (BBI608) Chemical Structure
CAS: 83280-65-3
產(chǎn)品質(zhì)控
批次：
純度：
99.72%
99.72
Napabucasin (BBI608)相關(guān)產(chǎn)品
| 相關(guān)靶點 | STAT1 STAT3 STAT5 STAT6 | 點擊展開 |
|---|---|---|
| 相關(guān)產(chǎn)品 | Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) SH-4-54 C188-9 (TTI-101) BP-1-102 HO-3867 Nifuroxazide AS1517499 Homoharringtonine (HHT) STAT5-IN-1 Ochromycinone (STA-21) HJC0152 APTSTAT3-9R STAT3-IN-1 SC-1 SH5-07 (SH-5-07) Scutellarin Narciclasine | 點擊展開 |
| 相關(guān)化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產(chǎn)物庫 酪氨酸激酶抑制劑分子庫 JAK-STAT信號通路庫 | 點擊展開 |
相關(guān)信號通路圖
細胞實驗數(shù)據(jù)示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息(PMID) |
|---|---|---|---|---|---|
| MDA-MB-231 | Function assay | 100 uM | 1 hr | Binding affinity to STAT3 in human MDA-MB-231 cells at 100 uM treated for 1 hr followed by thermolysin addition measured after 30 mins by DARTS-Western blot analysis | 30003778 |
| MDA-MB-231 | Function assay | 5 umol/L | 24 hrs | Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs by DHE staining based flow cytometry | 30003778 |
| MDA-MB-231 | Function assay | 5 umol/L | 24 hrs | Induction of superoxide generation in human MDA-MB-231 cells at 5 umol/L measured after 24 hrs in presence of NQO1 inhibitor dicoumarol by DHE staining based flow cytometry | 30003778 |
| human HaCaT cells | Function assay | 48 h | Antihyperproliferative activity against human HaCaT cells after 48 hrs by phase contrast microscopy, IC50=0.5 μM | 22845014 | |
| human DU145 cells | Function assay | 72 h | Anticancer activity against human DU145 cells after 72 hrs by XTT assay, IC50=0.02304 μM | 18829316 | |
| MDA-MB-231 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.34 μM. | 28558333 | |
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.66 μM. | 28558333 | |
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 0.74 μM. | 28558333 | |
| K562 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay, IC50 = 1 μM. | 30003778 | |
| MDA-MB-231 | Function assay | 4 hrs | Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-231 cells assessed as reduction in ratio of phosphorylated STAT3 to total STAT3 level after 4 hrs by HTRF assay, EC50 = 1.9 μM. | 30003778 | |
| MDA-MB-231 | Function assay | 4 hrs | Inhibition of STAT3 phosphorylation at Y705 in human MDA-MB-231 cells after 4 hrs by HTRF assay, EC50 = 2 μM. | 30003778 | |
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay, IC50 = 2.1 μM. | 30003778 | |
| HepG2 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HepG2 cells after 48 hrs by CCK-8 assay, IC50 = 10.2 μM. | 29604543 | |
| L02 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human L02 cells after 48 hrs by CCK-8 assay, IC50 = 18.7 μM. | 29604543 | |
| human HaCaT cells | Proliferation assay | Antiproliferative activity against human HaCaT cells, IC50=0.5 μM | 10479319 | ||
| KB cells | Cytotoxicity assay | Effective cytotoxic dose against KB cells was evaluated, ED50=4.2 μM | 9873618 | ||
| 點擊查看更多細胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Napabucasin (BBI608) 是一種口服具有活性的Stat3和癌細胞多能性抑制劑。 | |
|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||||
| 體外研究活性 | Napabucasin下調(diào)Stat3驅(qū)動的干細胞基因表達和癌癥干細胞性能，并有效抑制高度多功能性癌細胞的自我更新，IC50范圍為0.291~1.19 μM，而對正常干細胞沒有抑制作用。[1] | |||||
|---|---|---|---|---|---|---|
| 細胞實驗 | 細胞系 | 腫瘤干細胞 U87-MG，U118，COLO205，DLD1，SW480，HCT116，F(xiàn)aDu，ACHN，SNU-475，Huh7，HepG2，H1975，A549，H460，CAOV-3，SW-626，PaCa2 | ||||
| 濃度 | ~2 μM | |||||
| 孵育時間 | 72小時 | |||||
| 方法 | 對于各種癌癥干細胞，將球體解離，并在癌癥干細胞培養(yǎng)條件下接種到鍍層96孔板。培養(yǎng)72小時后，孔中加入指示劑量的化合物。加入72小時或24小時后，將CellTiter-Glo 2.0加入每個孔，熒光根據(jù)制造商的描述測量。IC50值使用GraphPad Prism軟件通過將四參數(shù)劑量響應(yīng)曲線擬合到標(biāo)準(zhǔn)數(shù)據(jù)計算。大部分細胞以5,000細胞/孔接種到96孔板。接種24小時后，細胞用指示濃度的化合物處理。存活率在72小時根據(jù)如上所述測定。 |
|||||
| 實驗圖片 | 檢測方法 | 檢測指標(biāo) | 實驗圖片 | PMID | ||
| Western blot |
CDK4 / Cyclin D1
STAT3 / β-catenin / c-Myc
| |||||